Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later‐line nivolumab monotherapy—The Asahikawa Gastric Cancer Cohort Study (AGCC)

BACKGROUND: Chemotherapy for advanced gastric cancer is recommended in the guidelines; however, later‐line treatment remains controversial. Since immune checkpoint inhibitors have been used for the treatment of various malignancies, trials have been performed for gastric cancer. A phase 3 trial indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Kazuyuki, Tanabe, Hiroki, Sato, Hiroki, Ishikawa, Chisato, Goto, Mitsuru, Yanagida, Naoyuki, Akabane, Hiromitsu, Yokohama, Shiro, Hasegawa, Kimiharu, Kitano, Yohei, Sugiyama, Yuya, Uehara, Kyoko, Kobayashi, Yu, Murakami, Yuki, Kunogi, Takehito, Sasaki, Takahiro, Takahashi, Keitaro, Ando, Katsuyoshi, Ueno, Nobuhiro, Kashima, Shin, Moriichi, Kentaro, Sato, Keisuke, Yuzawa, Sayaka, Tanino, Mishie, Taruiishi, Masaki, Sumi, Yasuo, Mizukami, Yusuke, Fujiya, Mikihiro, Okumura, Toshikatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729046/
https://www.ncbi.nlm.nih.gov/pubmed/34845844
http://dx.doi.org/10.1002/cam4.4461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729046/
https://www.ncbi.nlm.nih.gov/pubmed/34845844
http://dx.doi.org/10.1002/cam4.4461

Ejemplares similares